A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Recruiting

Phase 1

Phase 2

SPK-8011QQA Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Sponsor:

Hoffmann-La Roche

Code:

NCT07226206

Conditions

Hemophilia A

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SPK-8011QQ

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-15. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-08-04.